A Friend-ly New Resource for Biomarker Validation?
• By Mark Ratner
Merck is helping one of its top executives launch a new nonprofit venture, called Sage, which will develop disease models and provide an open access platform for researchers to gauge the effects of perturbing them. Pharma has never really supported the diagnostics industry apart from its own internal need for biomarkers. But along with supporting drug development, Sage could actually go to that very kind of diagnostics development that pharma has not wanted to do in the past.
Mark L. Ratner
It’s no surprise that SVP, cancer research Stephen Friend, MD, PhD, decided to leave Merck & Co. Inc. in February, four months after the company announced it was shuttering...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
